Article
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Mar 2018
Ramalingam Suresh S, Yang James C-H, Lee Chee Khoon, Kurata Takayasu, Kim Dong-Wan, John Thomas, Nogami Naoyuki, Ohe Yuichiro, Mann Helen, Rukazenkov Yuri, Ghiorghiu Serban, Stetson Daniel, Markovets Aleksandra, Barrett J Carl, Thress Kenneth S, Jänne Pasi A
Abstract excerpt
Purpose The AURA study ( ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naïve patients to examine clinical activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [ EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.